These results indicated that the combination treatment of anlotinib and gefitinib overcame the EGFR–TKI resistance, possibly by inhibiting the activation of VEGFR2 and the downstream Akt and ERK signaling transduction pathways.Several studies have demonstrated that EGFR–TKI combined with antiangiogenic drugs such as bevacizumab,11 apatinib,12, 18 and ramucirumab19 exhibit encouraging clinical activity in patients with NSCLC. This evidence concerns the gene KDR and non-small cell lung carcinoma.